Harpoon Therapeutics Inc is a biotechnology business based in the US. Harpoon Therapeutics shares (HARP) are listed on the NASDAQ and all prices are listed in US Dollars. Harpoon Therapeutics employs 95 staff and has a trailing 12-month revenue of around $23 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $0.97 |
|---|---|
| 52-week range | $0.93 - $8.98 |
| 50-day moving average | $1.88 |
| 200-day moving average | $3.58 |
| Wall St. target price | $8.78 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.31 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9701 from 2022-09-30
| 1 week (2022-09-23) | 3.09% |
|---|---|
| 1 month (2022-09-02) | -42.94% |
| 3 months (2022-07-01) | -48.40% |
| 6 months (2022-03-31) | -80.48% |
| 1 year (2021-10-01) | -87.55% |
|---|---|
| 2 years (2020-10-02) | -94.10% |
| 3 years (2019-10-02) | 14.23 |
| 5 years (2017-09-28) | N/A |
| Revenue TTM | $23 million |
|---|---|
| Gross profit TTM | $-48,470,000 |
| Return on assets TTM | -31.11% |
| Return on equity TTM | -129.13% |
| Profit margin | 0% |
| Book value | $0.81 |
| Market capitalisation | $31.2 million |
TTM: trailing 12 months
We're not expecting Harpoon Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Harpoon Therapeutics's shares have ranged in value from as little as $0.933 up to $8.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harpoon Therapeutics's is 1.4215. This would suggest that Harpoon Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.